Table 1

Baseline characteristics—entire cohort (general model and PSM model)

CharacteristicsGeneral modelPropensity score matched model
Tenofovir
(n=1439)
Entecavir
(n=1583)
Standardised differenceTenofovir
(n=1370)
Entecavir
(n=1370)
Standardised difference
Male gender841 (58.44%)926 (58.50%)−0.0011798 (58.25%)806 (58.83%)−0.0119
Age, years (SD)47.29 (11.16)46.66 (11.76)0.054646.92 (11.13)46.96 (11.75)−0.0155
 (Min, Max)(15.00, 80.00)(14.00, 93.00)(15.00, 80.00)(14.00, 93.00)
Liver cirrhosis483 (33.56%)567 (35.82%)0.0473464 (33.87%)465 (33.94%)0.0015
APRI>1.5563 (39.12%)640 (40.43%)0.0267540 (39.42%)544 (39.71%)0.006
FIB-4>3.25483 (33.56%)558 (35.25%)0.0355460 (33.58%)467 (34.09%)0.0108
DM105 (7.30%)159 (10.04%)−0.0978105 (7.66%)107 (7.81%)−0.0055
Hypertension178 (12.37%)226 (14.28%)−0.0561177 (12.92%)173 (12.63%)0.0087
BMI, kg/m2 (IQR)23.70 (21.99, 24.69)23.73 (21.86, 25.27)−0.0323.70 (21.97, 24.77)23.73 (21.85, 25.27)−0.0155
 (Min, Max)(14.02, 37.23)(13.42, 37.37)(14.02, 37.23)(13.42, 37.37)
Alcohol186 (12.93%)213 (13.46%)−0.0157177 (12.92%)180 (13.14%)−0.0065
Oesophageal varix54 (3.75%)88 (5.56%)−0.085853 (3.87%)60 (4.38%)−0.0257
AST (IQR)73.00 (46.00, 138.0)76.00 (47.00, 144.0)0.007273.00 (46.00, 138.0)76.00 (47.00, 144.0)−0.005
 (Min, Max)(4.00, 6955)(11.00, 5020)(4.00, 6955)(11.00, 5020)
ALT (IQR)94.00 (51.00, 194.0)98.00 (53.00, 201.0)−0.023194.50 (50.00, 196.0)98.00 (53.00, 200.0)−0.0147
 (Min, Max)(6.00, 5000)(8.00, 3421)(6.00, 5000)(8.00, 3421)
Bilirubin (IQR)0.89 (0.66, 1.20)0.90 (0.70, 1.24)−0.02780.89 (0.67, 1.20)0.90 (0.68, 1.24)−0.0387
(Min, Max)(0.21, 32.59)(0.15, 28.93)(0.21, 32.59)(0.15, 26.84)
Albumin (IQR)4.10 (3.80, 4.30)4.10 (3.80, 4.30)0.00544.10 (3.80, 4.30)4.10 (3.80, 4.30)0.0186
 (Min, Max)(2.00, 5.20)(1.81, 5.20)(2.00, 5.20)(1.81, 5.20)
Creatinine (IQR)0.84 (0.70, 1.00)0.86 (0.72, 1.00)−0.05070.84 (0.70, 1.00)0.86 (0.72, 1.00)−0.0154
 (Min, Max)(0.35, 11.09)(0.11, 11.09)(0.35, 11.09)(0.11, 8.55)
GGT (IQR)54.00 (29.00, 98.00)55.00 (31.00, 95.00)0.035153.00 (29.00, 95.00)55.00 (31.00, 95.00)0.0034
 (Min, Max)(1.97, 1698)(3.91, 1365)(1.97, 1698)(3.91, 1365)
PT INR (IQR)1.09 (1.03, 1.16)1.08 (1.02, 1.16)−0.04871.09 (1.03, 1.16)1.08 (1.02, 1.15)−0.0267
(Min, Max)(0.39, 4.30)(0.78, 2.84)(0.39, 4.30)(0.78, 2.84)
Platelet (IQR)168.0 (130.0, 211.0)164.0 (126.0, 205.0)0.0847168.0 (129.0, 210.0)166.0 (130.0, 208.0)0.0178
 (Min, Max)(20.00, 488.0)(8.00, 629.0)(20.00, 488.0)(8.00, 629.0)
Child-Pugh score (IQR)5.00 (5.00, 5.00)5.00 (5.00, 5.00)0.02955.00 (5.00, 5.00)5.00 (5.00, 5.00)−0.0237
 (Min, Max)(5.00, 12.00)(5.00, 12.00)(5.00, 12.00)(5.00, 12.00)
Positive HBeAg823 (57.19%)974 (61.53%)−0.0884807 (58.91%)814 (59.42%)−0.0104
HBV DNA (IQR)6.41 (5.34, 7.49)6.49 (5.28, 7.67)0.0126.39 (5.34, 7.49)6.51 (5.30, 7.71)−0.0059
 (Min, Max)(0.77, 9.00)(0.77, 9.23)(0.77, 9.00)(0.77, 9.23)
AFP (IQR)5.00 (3.00, 10.91)4.93 (3.14, 8.11)0.06065.00 (3.00, 10.90)4.80 (3.08, 8.00)0.0623
 (Min, Max)(0.92, 1469)(0.50, 4016)(0.92, 1174)(0.50, 1892)
Treatment initiation
Before December 201215 (1.04%)1348 (85.15%)15 (1.09%)1166 (85.11%)
Since December 20121424 (98.96%)235 (14.85%)1355 (98.91%)204 (14.89%)
  • AFP, alpha-fetoprotein; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; BMI, Body mass index; DM, Diabetes Mellitus; FIB-4, fibrosis 4 index; GGT, gamma- glutamyltransferase; HBV, hepatitis B virus; Max, maximum; Min, minimum; PT INR, prothrombin time international normalised ratio.